Market Cap | 17.65M | P/E | - | EPS this Y | 27.90% | Ern Qtrly Grth | - |
Income | -41.5M | Forward P/E | -0.48 | EPS next Y | 8.10% | 50D Avg Chg | 29.00% |
Sales | 57.06M | PEG | 0.03 | EPS past 5Y | - | 200D Avg Chg | 6.00% |
Dividend | N/A | Price/Book | 0.38 | EPS next 5Y | -14.58% | 52W High Chg | -76.00% |
Recommedations | 2.00 | Quick Ratio | 3.15 | Shares Outstanding | 7.88M | 52W Low Chg | 113.00% |
Insider Own | 6.29% | ROA | -27.32% | Shares Float | 6.93M | Beta | 1.42 |
Inst Own | 22.56% | ROE | -78.71% | Shares Shorted/Prior | 83.58K/111.46K | Price | 2.24 |
Gross Margin | 33.21% | Profit Margin | -72.73% | Avg. Volume | 167,770 | Target Price | 2.27 |
Oper. Margin | -70.87% | Earnings Date | Oct 31 | Volume | 106,491 | Change | 0.00% |
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Oppenheimer | Perform | May 9, 23 |
Oppenheimer | Outperform | Nov 11, 22 |
Oppenheimer | Outperform | Nov 4, 21 |
Oppenheimer | Outperform | Sep 22, 21 |
Oppenheimer | Outperform | May 12, 20 |
Oppenheimer | Outperform | Apr 2, 19 |
Canaccord Genuity | Buy | Nov 1, 18 |
Canaccord Genuity | Buy | Apr 10, 18 |
Cowen & Co. | Outperform | Feb 21, 18 |